Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study

Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study

Background: Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is characterized by chronic relapsing intestinal inflammation. There are few data on the efficacy and safety in clinical practice of infliximab (CT-P13) in subcutaneous formulation (SC) for the treatment...

Full description

Bibliographic Details
Main Authors:	Jose M. Huguet, Victor García-Lorenzo, Lidia Martí, Jose María Paredes, Jose Joaquin Ramírez, Miguel Pastor, Lucia Ruiz, Ana Sanahuja, Pilar Timoneda, Laura Sanchís, Gloria Alemany Pérez, Marta Maia Boscá-Watts
Format:	Article
Language:	English
Published:	MDPI AG 2022-08-01
Series:	Biomedicines
Subjects:	infliximab CT-P13 infliximab trough level inflammatory bowel disease Crohn’s disease ulcerative colitis
Online Access:	https://www.mdpi.com/2227-9059/10/9/2130

Similar Items

Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab
by: Jihye Park, et al.
Published: (2023-05-01)

Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure
by: June Hwa Bae, et al.
Published: (2024-07-01)

Refractory Duodenal Crohn's Disease Successfully Treated with Infliximab
by: You Lim Kim, et al.
Published: (2014-01-01)

Early intestinal obstruction after infliximab therapy in Crohn’s disease
by: Mitsuro Chiba, et al.
Published: (2019-08-01)

Successful Treatment of Postoperative Fistula with Infliximab in a Patient with Crohn's Disease
by: Seong Yeon Jeong, et al.
Published: (2014-01-01)

Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease
by: So Yoon Choi, et al.
Published: (2023-06-01)

Long-Term Clinical Outcomes of Korean Patient With Crohn's Disease Following Early Use of Infliximab
by: Nam Hee Kim, et al.
Published: (2014-10-01)

Long-Term Clinical Remission in Biologically Naïve Crohn’s Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
by: Tsutomu Mizoshita, et al.
Published: (2016-06-01)

Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
by: Yoon Suk Jung, et al.
Published: (2021-01-01)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease
by: Luis Eduardo Miani Gomes, et al.
Published: (2019-04-01)

Exploring treatment of inflammatory bowel disease with infliximab in the Middle East and Northern Africa: An analysis of the HARIR observational cohort study
by: Othman Alharbi, et al.
Published: (2023-01-01)

Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars
by: O. V. Knyazev, et al.
Published: (2021-02-01)

Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn’s disease
by: Kouzhu Zhu, et al.
Published: (2024-08-01)

Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
by: Eirini Theodoraki, et al.
Published: (2021-10-01)

Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab Pioderma gangrenoso asociado a colitis ulcerosa: respuesta a infliximab
by: A. López San Román, et al.
Published: (2004-06-01)

Fecal Calprotectin at Postinduction Is Capable of Predicting Persistent Remission and Endoscopic Healing after 1 Year of Treatment with Infliximab in Pediatric Patients with Crohn’s Disease
by: Yoo Min Lee, et al.
Published: (2024-05-01)

Cortical Vein Thrombosis after Infliximab Treatment for Crohn’s Disease
by: Saeed Razmeh, et al.
Published: (2021-03-01)

Loss of Response to Long-Term Infliximab Therapy in Children with Crohn’s Disease
by: George Alex, et al.
Published: (2013-10-01)

Serum infliximab levels and clinical response in hidradenitis suppurativa
by: Erwin Benassaia, et al.
Published: (2023-06-01)

Infliximab‐induced seizures in a patient with Crohn’s disease: a case report
by: Zhijie Lv, et al.
Published: (2021-04-01)

Deep-Learning, Radiomics and Clinic Based Fusion Models for Predicting Response to Infliximab in Crohn’s Disease Patients: A Multicentre, Retrospective Study
by: Cai W, et al.
Published: (2024-10-01)

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
by: van der Maas Aatke, et al.
Published: (2012-09-01)

Promising effect of infliximab on the extent of involvement in ulcerative colitis
by: Peyman Adibi, et al.
Published: (2011-01-01)

High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients
by: Manuel Sutter, et al.
Published: (2021-08-01)

The risk of COVID-19 in IBD patients is increased by urban living and is not influenced by disease activity or intravenous biologics
by: Margaux Lelong, et al.
Published: (2023-08-01)

Infliximab‐induced autoimmune hepatitis requiring liver transplantation
by: Frederick Wong, et al.
Published: (2019-11-01)

Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease
by: Cheng-Chun Ji, et al.
Published: (2017-04-01)

Predictors of infliximab efficacy in patients with severe attack of ulcerative colitis
by: A. O. Golovenko, et al.
Published: (2013-10-01)

Infliximab for Anoperineal Lesions in Crohn's Disease: Remission Appears to be Based on Rapid Combination Therapy at High Doses
by: Nadia Fathallah, et al.
Published: (2022-06-01)

Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease
by: Ju Young Kim, et al.
Published: (2021-07-01)

Persistence of Second and Third-Line Biologics in Inflammatory Bowel Disease: A Multi-Centre Cohort Study
by: Timothy P. Hanrahan, et al.
Published: (2022-12-01)

Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease
by: Jang Wook Lee, et al.
Published: (2016-04-01)

The impact of medication belief on adherence to infliximab in patients with Crohn’s disease
by: Shuyan Li, et al.
Published: (2023-08-01)

Efficacy of Infliximab for the Treatment of Oral Manifestation of Crohn’s Disease
by: Aibar Aginbay, et al.
Published: (2022-11-01)

CORRELATION BETWEEN TROUGH LEVELS OF INFLIXIMAB AND POSTOPERATIVE ENDOSCOPIC RECURRENCE IN CROHN’S DISEASE PATIENTS SUBMITTED TO ILEOCOLONIC RESECTIONS: A SYSTEMATIC REVIEW
by: Fernanda da Silva Barbosa BARAÚNA, et al.
Published: (2021-04-01)

Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease
by: So Yoon Choi, et al.
Published: (2017-01-01)

External Evaluation of Population Pharmacokinetic Models and Bayes-Based Dosing of Infliximab
by: Celine Konecki, et al.
Published: (2021-08-01)

Combined therapy with early initiation of infliximab following drainage of perianal fistulising Crohn’s disease: a retrospective cohort study
by: Ping Zhu, et al.
Published: (2022-01-01)

Prognostic factors for the efficacy of infliximab in patients with luminal fistulizing Crohn’s disease
by: Ye Ma, et al.
Published: (2023-03-01)

A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients
by: Alejandro Pérez-Pitarch, et al.
Published: (2015-03-01)